Accreditation/
Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource, LLC, designates this live activity for a maximum of 11.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 11.0 Contact Hours.
Acknowledgment of Commercial Support
This activity is supported by educational grants from AbbVie Inc., AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Celgene Corporation., Genentech, Lilly, Pfizer, Merck Sharp & Dohme Corp, and Takeda Oncology.
For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
16th Annual Winter Lung Cancer Conference™
Physicians' Education Resource® (PER®) is excited to announce that The Miami Lung Cancer Conference has joined with the Winter Lung Cancer Conference to expand your educational opportunities!
Friday, January 25, 2019 – Sunday, January 27, 2019
Eden Roc Miami
4525 Collins Avenue
Miami Beach, FL 33140
Phone: 305-531-0000
Website: www.edenrochotelmiami.com
16th Annual Winter Lung Cancer Conference Overview
As the field of lung cancer therapy undergoes another revolution, we are pleased to invite you to the upcoming 16th Annual Winter Lung Cancer Conference™. This meeting will provide you with the most cutting-edge research and practical information for the care of your patients, as well as offer a preview of new agents and techniques likely to be the future of lung cancer treatment.
This year, we are excited to combine the historic Winter Lung Cancer Conference™ with PER’s own Miami Lung Cancer Conference® to offer you a world-class continuing medical education event for the treatment of patients with lung cancer. This year’s meeting will continue the traditional educational format of the Winter Lung Cancer Conference™ while incorporating the dynamic Medical Crossfire® exchanges that Miami Lung is best known for.
This combined program, led by world-class thoracic oncologists, will offer you the chance to learn from and interact with international experts in several therapeutic areas, including immunotherapy, targeted agents, and combined modality therapy. The program will offer extended segments on these topics, allowing for audience engagement and interactive discussion even during the didactic presentations. Throughout the program, the Medical Crossfire® segments and question-and-answer sessions will provide the opportunity to consult with faculty and your community-based peers. Come to learn, but also to share your personal experiences and best practices in lung cancer management.
Attending this year’s conference will help you learn state-of-the-art care, including:
- How to navigate the increasing options for immunotherapy-based regimens in metastatic disease
- How to utilize molecular testing at diagnosis and following progression on next-generation inhibitors
- Guides to select the best initial therapy for oncogene-driven NSCLC
- The use of consolidation immunotherapy in locally advanced disease
- Changes to treatment paradigms in the management of disease progression
This unified meeting has been fully expanded to accommodate you, the learner. Join us from January 25-27, 2019 in Miami, Florida. We look forward to seeing you there!
Acknowledgment of Commercial Support
This activity is supported by educational grants from AbbVie Inc., AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Celgene Corporation., Genentech, Lilly, Merck Sharp & Dohme Corp, Pfizer, and Takeda Oncology.
Learning Objectives
At the conclusion of this activity, you should be better prepared to:
- Incorporate molecular testing strategies to inform treatment selection in patients with oncogene-driven NSCLC
- Discuss emerging approaches for patient selection for immunotherapy and targeted agents
- Evaluate treatment strategies for early-stage and locally advanced lung cancer
- Discuss the use of cytotoxic, targeted, and other systemic agents in the management of patients with lung cancer with or without oncogenic drivers
- Apply immunotherapeutic strategies in patients with thoracic malignancies along the disease continuum
- Explain approaches to mitigate and manage treatment-related adverse events in patients with lung cancer
For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
Target Audience
This educational activity is directed toward oncologists involved in the treatment and management of patients with lung cancers. Nurse practitioners (NPs), nurses, physician assistants (PAs), pharmacists, researchers, fellows, and other healthcare professionals interested in the treatment of lung cancers may also participate.
Program Chairs
Rogerio C. Lilenbaum, MD
Professor of Medicine in Medical Oncology
Chief Medical Officer of Smilow Cancer Hospital – Yale New Haven Health
New Haven, CT
Mark A. Socinski, MD
Executive Medical Director
Florida Hospital Cancer Institute
Orlando, FL
Heather A. Wakelee, MD
Professor, Medicine (Oncology)
Stanford University Medical Center
Stanford, CA
Julie R. Brahmer, MD, MSc
Director, Thoracic Oncology Program
Interim Director, Sidney Kimmel Cancer Center at Johns Hopkins Bayview
Professor of Oncology
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD
Register
You must be logged in to PER to register for this meeting
Or Register for PER now
*Required Fields
Login Information
Registration Information
In case of onsite emergency:
Professional Information
Specialties*
Assumption of Risk and Waiver of Liability Relating to Coronavirus/COVID-19
I understand that the hazards of the novel coronavirus ("COVID-19") and have reviewed the Centers for Disease Control and Prevention ("CDC") current guidelines in regards to COVID-19. I acknowledge that while Physicians' Education Resource, LLC ("PER") ("Company") has put in place preventative measures to reduce the spread of COVID-19, Company cannot guarantee that I or anyone else will not become infected with COVID-19. I attest that if within the fourteen (14) days prior to the event, I am experiencing any symptoms of COVID-19, or I have been in close contact with anyone that has been diagnosed with COVID-19, then I will not attend the Activities. I shall follow any safety, social distancing, masking, and hygiene protocols that have been implemented at the Activities.
I hereby willingly and voluntarily choose to attend this PER event and related activities ("Activity"). I acknowledge and fully assume the risk and hazards of exposure to COVID-19 and that such exposure or infection may result in personal injury, illness, permanent disability, and death to myself, my spouse, children, unborn child, or relatives. I hereby release covenant not to sue, forever discharge, and hold harmless Company and its affiliates from all liability claims and demands of whatever kind of nature, either in law or in equity, which arise or may hereafter arise from participating in the Activities. I assume all risks of losses, damages, or injuries that may be sustained while participating in the Activity. I understand and agree that this release includes any Claims based on the actions, omissions, or negligence of the venue, employees, vendors, agents, and representatives, whether a COVID-19 infection occurs before, during, or after participation in the Activity.
* By checking this box, you have read and understand the above and agree to its terms.
